Physician profile
Osman Farooq
NPI 1700034196
$16,122.62
in general payments reported to CMS, 2019-2025
20 companies · $5,458 in 2025
The $5,458 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $298 · 2021: $2,158 · 2022: $3,099 · 2023: $2,672 · 2024: $1,416 · 2025: $5,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,180 · Food and Beverage: $4,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,180.00 |
| Food and Beverage | $4,365.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $11,368.56 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Ucb, INC. | $1,250.09 | 2022-2025 | Nayzilam, Fintepla, Briviact |
| Biogen, INC. | $843.32 | 2019-2025 | Spinraza |
| Jazz Pharmaceuticals INC. | $675.99 | 2022-2025 | Epidiolex |
| Pyros Pharmaceuticals, INC. | $482.01 | 2024 | Vigpoder |
| Sk Life Science, INC. | $411.31 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $232.28 | 2019 | |
| Neurelis, INC. | $176.47 | 2020-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $140.52 | 2023-2025 | Daybue |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $100.00 | 2019 | |
| Upsher-Smith Laboratories LLC | $87.19 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $85.77 | 2019 | |
| Itf Therapeutics LLC | $52.72 | 2024 | |
| Mallinckrodt Hospital Products INC. | $48.24 | 2020 | |
| Supernus Pharmaceuticals, INC. | $39.61 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $34.57 | 2024 | Hizentra |
| Ptc Therapeutics, INC. | $32.38 | 2022-2023 | Emflaza |
| Novartis Pharmaceuticals Corporation | $21.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.55 | 2019 | |
| Biomarin Pharmaceutical INC. | $19.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.